# **Overview of the NIH Grant System**

Andrew A. Bremer, M.D., Ph.D. Chief, Pediatric Growth and Nutrition Branch Acting Chief, Pregnancy and Perinatology Branch



*Eunice Kennedy Shriver* National Institute of Child Health and Human Development




#### **National Institutes of Health**



- Much of the biomedical research in the United States is supported by the Federal government, primarily the National Institutes of Health (NIH)
- One agency of 10 within the U.S. Department of Health and Human Services (HHS)
- Comprises 27 Institutes and Centers as well as Offices (ICOs)




#### **U.S. Dept. of Health and Human Services**






#### Balanced National Biomedical Research Portfolio






## **National Institutes of Health**






### **A Typical Institute/Center**






# Total Spending for United States – FY2016






#### United States Discretionary Budget Proposed 2016






#### FY 2012 Senate Approved Budget NIH Funding By Institute/Center<sup>\*</sup> (\$ in Millions)



\*Includes funding for Type 1 Diabetes.



### **Review Process for a Research Grant**



## **Review System for Grant Applications**

#### Scientific Review Group (SRG) – First Level

- Independent outside review
- Evaluate scientific merit, significance
- Recommend length and level of funding

#### **Output:** Priority Score and Summary Statement



- programmatic priorities
- Must also Pass Administrative Review

#### Output: Awards or Resubmission



# **Scoring System**

Reviewers have been instructed to score each of the five review criteria, and the overall impact/priority of each application, on a 9-point rating scale according to the following descriptions and additional guidance:

| Score | Descriptor   | Additional Guidance on Strengths/Weaknesses         |  |
|-------|--------------|---|--|
| 1     | Exceptional  | Exceptionally strong with essentially no weaknesses |  |
| 2     | Outstanding  | Extremely strong with negligible weaknesses         |  |
| 3     | Excellent    | Very strong with only some minor weaknesses         |  |
| 4     | Very Good    | Strong but wit numerous minor weaknesses            |  |
| 5     | Good         | Strong but with at least one moderate weakness      |  |
| 6     | Satisfactory | Some strengths but also some moderate weaknesses    |  |
| 7     | Fair         | Some strengths but with at least one major weakness |  |
| 8     | Marginal     | A few strengths and a few major weaknesses          |  |
| 9     | Poor         | Very few strengths and numerous major weaknesses    |  |

Minor Weakness: An easily addressable weakness that does not substantially lessen impact


Moderate Weakness: A weakness that lessens impact

Major Weakness: A weakness that severely limits impact




# Life Cycle of a Research Concept

#### EXTRAMURAL COMMUNITY



P=program, R=review, C=contracts, G=grants

#### **Overview of NIH Grants Process**





### **Timeline: New Applications**

| Receipt Date | Scientific<br>Review | Council Review | Award Date |
|--------------|----------------------|----------------|------------|
| February 5   | July                 | October        | December   |
| June 5       | October              | January        | April      |
| October 5    | March                | Мау            | July       |











#### **Thank You!**

• <u>andrew.bremer@nih.gov</u>



